LSV Asset Management Takes $31.26 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

LSV Asset Management acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 55,600 shares of the biopharmaceutical company’s stock, valued at approximately $31,262,000. LSV Asset Management owned about 0.05% of Regeneron Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of REGN. Skylands Capital LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth $1,161,000. Cibc World Market Inc. grew its stake in Regeneron Pharmaceuticals by 232.3% during the 3rd quarter. Cibc World Market Inc. now owns 15,733 shares of the biopharmaceutical company’s stock worth $8,846,000 after buying an additional 10,999 shares during the last quarter. Caprock Group LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $1,471,000. ING Groep NV increased its position in Regeneron Pharmaceuticals by 136.0% during the 3rd quarter. ING Groep NV now owns 108,877 shares of the biopharmaceutical company’s stock valued at $61,218,000 after buying an additional 62,749 shares in the last quarter. Finally, Krilogy Financial LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $1,176,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,636 shares of company stock valued at $2,862,920 over the last ninety days. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.5%

NASDAQ:REGN opened at $803.17 on Friday. The firm has a market capitalization of $84.41 billion, a P/E ratio of 19.33, a PEG ratio of 2.11 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The company’s fifty day moving average price is $762.17 and its 200-day moving average price is $665.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $12.07 earnings per share. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.05%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on REGN. Royal Bank Of Canada boosted their price target on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Wells Fargo & Company boosted their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Zacks Research lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $793.81.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.